H1: Advar Pharma PARABOLAN Product Information

Advar Pharma PARABOLAN is associated with the compound trenbolone hexahydrobenzylcarbonate, an ester of trenbolone that is also known as trenbolone cyclohexylmethylcarbonate. PubChem identifies Parabolan as a synonym for this compound and lists CAS number 23454-33-3.

H2: PARABOLAN Product Details

Parabolan is historically associated with trenbolone hexahydrobenzylcarbonate and an injectable pharmaceutical formulation. Historical French pharmaceutical records identify Parabolan as a solution for injection manufactured by Negma and document that its marketing was discontinued in 1997.

The compound has also been examined in scientific literature describing the structural characteristics of trenbolone and its esterified forms, including trenbolone hexahydrobenzylcarbonate.

For the Advar Pharma product, the exact concentration, vial or ampoule size, excipients, batch information, and current regulatory status should be confirmed from the actual product packaging and manufacturer documentation. These details should not be inferred solely from the name PARABOLAN because products using the same or similar names may have different specifications.

PARABOLAN should also be distinguished from other trenbolone esters such as trenbolone acetate. The ester attached to trenbolone is an important part of the compound’s chemical identity and formulation characteristics.

H3: FAQ: Advar Pharma PARABOLAN

What is Advar Pharma PARABOLAN?
Advar Pharma PARABOLAN is associated with trenbolone hexahydrobenzylcarbonate, historically known by the Parabolan name.

What is the active compound associated with Parabolan?
Parabolan is a synonym associated with trenbolone hexahydrobenzylcarbonate.

Is Parabolan the same as trenbolone acetate?
No. They are different trenbolone esters. Parabolan is associated with trenbolone hexahydrobenzylcarbonate, while trenbolone acetate contains a different ester.

What strength is Advar Pharma PARABOLAN?
The Advar-specific strength should be confirmed from the actual packaging or manufacturer documentation. No concentration should be assumed from the product name alone.

Was Parabolan historically marketed as a pharmaceutical product?
Yes. French pharmaceutical records document Parabolan as an injectable product that was later discontinued, with marketing ending in 1997.

What should be checked when evaluating the product?
Check the active ingredient, stated concentration, dosage form, packaging, batch or lot information, manufacturer details, labeling, and applicable regulatory requirements.